← All trials
NCT05919082
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2023
- Primary completion
- Jun 19, 2024
- Completion date
- Jul 2, 2024
- First posted
- Jun 26, 2023
- Last posted
- Nov 27, 2023
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leo PharmaLead sponsor
- Leo PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.